EXEL  valuation analysis

Name: Exelixis Inc
Description: Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Nov 02, 2021
Market cap: $6.15B (651st)
Sales(TTM): $1.25B (933rd)
Earnings(TTM): $164.28M (798th)

FFER: 1.77 (why)
Actual price: $19.10
FFEThis is Exelixis Inc's the estimated price. FFEs are the denominator of the FFER ratio.: $10.76
Quantile: EXEL is expensive given its fundamentals.
Prices as of EOD 2021-12-22
Price & Estimates
Sales & Earnings history (TTM)
  • Exelixis Inc's sales grew by 30.9% ($957.80M to $1.25B) over one year against a market average growth of 16.3%.
Earnings / MarketCap
Exelixis Inc
"Biotechnology" industry
Sales / MarketCap
Exelixis Inc
"Biotechnology" industry
Book / MarketCap
Exelixis Inc
"Biotechnology" industry
Equity / Assets
Exelixis Inc
"Biotechnology" industry